Changes to the label for tilmicosin injection were approved by the FDA to address the risk to humans who handle or administer the drug
Officials from the FDA have approved revised labeling of tilmicosin injection (Micotil 300; Elanco Animal Health) for certain cattle and sheep.1 The drug is indicated to treat bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni; and ovine respiratory disease associated with Mannheimia haemolytica.2
The change of labeling is to help protect those who administer this drug. An accidental human injection of tilmicosin can lead to severe cardiac effects, with some cases resulting in hospitalization, prolonged medical care, and even death, according to the FDA.1
Elanco Animal Health worked with the FDA to help decrease the number of accidental human injections and other potential ways of exposure including through the mouth, on the skin, or in the eye. The product's new packaging has the drug in a tamper-proof shroud and requires a quick-connect device with a tube-fed safety syringe provided by Elanco and its distributors.1 The new labeling will also include safe use and handling instructions located on the shroud, and an updated warning language about animal and user safety.
Anyone who handles tilmicosin injection must be trained appropriately to use it safely in a controlled setting with cattle correctly restrained. In 2017, the FDA published an Animal Drug Safety Communication to alert veterinarians, farm workers, physicians, emergency medical technicians, cattle and sheep owners, and other health care providers about the hazards of accidental exposure to tilmicosin.3
Humans exposed to tilmicosin should seek medical care immediately. Those who have been accidentally injected with less than 0.5 ml (1/10 teaspoon) are at risk of pain and bleeding at the injection site with larger volumes associated with dizziness, nausea, rapid heart rate, and death.1
References
Oral solution approved by the FDA for canine heart failure
November 22nd 2024Vetmedin Solution from Boehringer Ingelheim is indicated for treatment of cases caused by myxomatous mitral valve disease or dilated cardiomyopathy and is the first oral solution approved by the FDA for this use in dogs
Read More